Adoption by Design: Turning a Validated Diagnostic into Routine NHS Care

The UK has no shortage of promising diagnostics. What it often lacks is a credible route from a favourable study to the place where a result would actually alter a decision. In 2026, that gap is less about scientific validity than about adoption design: the unglamorous work of turning an assay into a commissioned, owned and funded part of a pathway. The last mile is not simply a formulary line. It is a chain of decisions about evidence, budget, workforce, data and accountability.

A good assay is not an adoption plan

Diagnostic innovators are trained to prove that a test can detect what it is meant to detect, in the population and conditions specified. They are less often trained to answer the questions that determine whether it will be used: which clinical decision changes, who is accountable for acting on the result, how the test is paid for, and what happens to the pathway when the pilot ends. Those are not commercial afterthoughts. They are the conditions under which translation succeeds or stalls.

The NHS does not adopt a test because it is technically elegant. It adopts a test because a pathway can absorb it without creating unmanaged work, unwarranted variation or an unfunded liability. That distinction matters for every innovator who assumes that a favourable evaluation will be followed by routine use.

Evaluation is necessary, but it is not the whole gate

NICE assessment can clarify clinical and cost effectiveness, and it remains a critical signal of rigour. But evaluation is a gate, not a guarantee. A positive assessment does not by itself create a budget line, appoint a pathway owner or persuade a primary care network to change its referral habits. Nor does it resolve the practical questions that determine whether a result is returned in a form that a clinician can act on without a specialist telephone call.

Too often, the evaluation dossier and the adoption plan are written by different people with different assumptions. The evaluator asks whether the test is effective. The commissioner asks whether it is affordable in the current financial year. The clinician asks whether it will help the next patient in front of them. The patient asks whether it will change what happens next. A credible adoption design has to hold all four questions together.

Budget silos reward the wrong question

Integrated care boards are expected to plan across systems, but budgets still behave as if care were separable. A test that saves hospital bed days may sit in a primary care or community budget. A result that reduces emergency admissions may increase laboratory workload. A pathway that improves outcomes over twelve months may look expensive in a three-month pilot. When the commissioner asks whether a test is affordable in-year, the answer may be no even when the test is cost-effective across the system.

This is not a failure of individual commissioners. It is a design problem. Adoption requires a named owner for the whole pathway, not just for the test. It requires clarity about which budget pays for the assay, the phlebotomy, the transport, the reporting, the clinical review and the repeat testing — and which budget receives the saving. Without that clarity, a validated diagnostic becomes a discretionary extra, taken up unevenly by enthusiasts and quietly dropped when the project funding ends.

Formulary inclusion without a funded pathway is a library card, not a service. It signals that a test is available in principle while leaving the operational burden to whoever happens to pick it up.

The missing business case is usually a missing operational case

Many adoption failures are presented as evidence problems when they are actually operational ones. The business case must include the work that the assay creates: sample collection, laboratory capacity, information technology, report design, clinical review, audit and safety-netting. If the test shifts work into general practice without resource, adoption will be slow and uneven. If it creates a new alert that no one owns, it will be ignored or over-investigated.

Adoption design must be as rigorous as the assay itself. That means modelling the pathway as it will actually run, not as it appears in a study protocol. It means testing the report format with clinicians who will use it. It means defining the repeat threshold, the referral route and the stop rule before launch, not after the first audit reveals unwarranted variation.

Questions to ask before the pilot is celebrated

Before a pilot is presented as a success, innovators, clinicians and commissioners should be able to answer a short set of practical questions:

• Which single clinical decision will this result change, and for which patient group?
• Who owns the pathway after the pilot, and what happens when project funding ends?
• Which budget pays for the test, the staff time and the follow-up, and which budget receives the saving?
• What is the disinvestment or stop rule if uptake, outcomes or cost do not meet expectations?
• Can the result be reported in a form that primary care can act on without a specialist telephone call?
• What data will be collected to show whether adoption is equitable, not just enthusiastic?
• What will clinicians stop doing if they start using this test, and who will support that disinvestment?

These questions are not obstacles to innovation. They are the design specification for translation.

Adoption design as translational care

Translating biomedical research into everyday care is often described as a communication task: explain the science clearly and adoption will follow. It is also a design task. The sector needs adoption literacy alongside scientific literacy — an understanding of how evidence becomes a pathway, how a pathway becomes a budget, and how a budget becomes routine practice.

A diagnostic that cannot be commissioned, explained and audited is not yet a standard of care. In 2026, the most useful innovation may be a pathway that makes the test ordinary: easy to order, easy to interpret, easy to fund and easy to stop when it is not working. That is less glamorous than the assay, but it is the last mile that determines whether good diagnostics actually change care.